Organisation paid for research Program year 2022 Source: CMS Open Payments

Willamette Valley Clinical Studies

Neither a doctor nor a teaching hospital

Research payments

$46,771

11 payments

Through program year 2022, Willamette Valley Clinical Studies is reported as receiving $46,771 in research payments, across 11 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2022	Research	$15,431	4
2019	Research	$31,341	7

Breakdown

Who paid Research payments · program years 2019–2022

Sanofi US Services Inc. $31,341 7 payments
Pfizer Inc. $15,431 4 payments

Studies the money was for Research payments · program years 2019–2022

A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place $16,765 3 payments
An Interventional Efficacy and Safety Phase 2 Randomized Doubleblind 2Arm Study to Investigate A Repeat 5Day Course of Nirmatrelvirritonavir Compared to Placeboritonavir in Participants at Least 12 Years of Age With Rebound of Covid19 Symptoms and Rapid Antigen Test Positivity $15,431 4 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who $8,434 2 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have $5,142 1 payment
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr $1,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.